Survival Outcomes with Immune Checkpoint Signatures and Data Interoperability across Melanoma Registry Data

Abstract

The advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape for advanced melanoma, significantly improving long-term survival rates for a subset of patients. However, predicting individual survival outcomes remains a complex challenge due to the heterogenous nature of tumor-immune system interactions and the highly fragmented state of real-world clinical data. This paper presents a comprehensive investigation into the role of immune checkpoint signatures as predictive biomarkers for melanoma survival, emphasizing the critical necessity of data interoperability across diverse clinical registries. By leveraging standard ontologies and common data models, heterogeneous data sources including genomic profiles, electronic health records, and pathological assessments were harmonized into a unified analytical framework. A novel immune checkpoint expression signature was derived and evaluated against real-world survival data. The integration process demonstrated that achieving semantic interoperability drastically reduces data loss and improves the statistical power of predictive modeling. Survival analyses indicate that patients exhibiting a high immune checkpoint signature score have significantly distinct overall survival trajectories compared to those with low scores, independent of traditional clinical staging. These findings underscore the immense potential of combining transcriptomic signatures with interoperable clinical registries to facilitate precision oncology, optimize therapeutic decision-making, and ultimately improve patient outcomes in melanoma.